Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date-Reference-Cited by-同舟云学术

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Published:2021-02 Issue: Volume:Volume 15 Page:453-462
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Moussa Mohamad,Papatsoris Athanasios,Abou Chakra Mohamed,Dellis Athanasios

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference30 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita

3. Cancer Stat Facts: Bladder Cancer. NIH NCI: surveillance, epidemiology and end results programme; 2019. Available from: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 19, 2021.

4. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

2. [²²⁵Ac]Ac/[⁸⁹Zr]Zr-labeled N4MU01 radioimmunoconjugates as theranostics against nectin-4 positive triple negative breast cancer;2024-03-08

3. Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin;Journal of Cutaneous Pathology;2024-01-10

4. Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral;Ciencia en Desarrollo;2023-07-19

5. Antibody–Drug Conjugates in the Treatment of Urothelial Cancer;BioDrugs;2023-05-31